Key Insights

Highlights

Treatment Research

2 treatments under study, led by Zoledronic Acid Fresenius Kabi 4 Mg5 Ml Koncentrat Till Infusionsvätska Lösning

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
Showing all 1 trials

Research Network

Common Treatments

  • Zoledronic Acid Fresenius Kabi 4 Mg5 Ml Koncentrat Till Infusionsvätska Lösning1
  • Denosumab1

Activity Timeline